Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Randomized, Double-Blind, Placebo-Controlled Study
- 1 March 2014
- journal article
- research article
- Published by Elsevier BV in Journal of Pain and Symptom Management
- Vol. 47 (3), 542-550
- https://doi.org/10.1016/j.jpainsymman.2013.05.003
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- Management of Intractable Nausea and Vomiting in Patients at the End of LifeJama-Journal Of The American Medical Association, 2007
- Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost ImplicationsJournal of Clinical Oncology, 2005
- The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study GroupJournal of Clinical Oncology, 2003
- Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonistsEuropean Journal of Cancer, 2003
- Olanzapine in the Management of Cancer PainJournal of Pain and Symptom Management, 2002
- Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case reportPsycho‐Oncology, 2000
- Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice GuidelinesJournal of Clinical Oncology, 1999
- Radioreceptor Binding Profile of the Atypical Antipsychotic OlanzapineNeuropsychopharmacology, 1996
- Control of Chemotherapy-Induced EmesisThe New England Journal of Medicine, 1993